Barbara Döring
University of Giessen
23 Papers
209 Citations
Barbara Döring is an academic researcher from University of Giessen. The author has contributed to research in topics: Organic anion transporter 1 & Organic anion-transporting polypeptide. The author has an hindex of 19, co-authored 23 publications.
Chat about Author
Papers
Kinetics of the bile acid transporter and hepatitis B virus receptor Na+/taurocholate cotransporting polypeptide (NTCP) in hepatocytes.
TL;DR: Myr-preS1 virus binding to NTCP, necessary for productive HBV infection, interferes with the physiological bile acid transport function of N TCP, which opens a completely new way for an efficient management ofHBV infection by the use of NTCp-directed drugs.
144
The SLC10 carrier family: transport functions and molecular structure.
TL;DR: Each individual member of the SLC10 family is described step-by-step in terms of expression, localization, substrate pattern, as well as protein topology with emphasis on the three functional SLC 10 carrier members.
125
Phase 0 and phase III transport in various organs: combined concept of phases in xenobiotic transport and metabolism.
Barbara Döring,Ernst Petzinger +1 more
TL;DR: This review deals with the function of drug carriers in various organs and their impact on drug metabolism and elimination.
122
Cloning and Functional Characterization of Human Sodium-dependent Organic Anion Transporter (SLC10A6)
Joachim Geyer,Barbara Döring,Kerstin Meerkamp,Bernhard Ugele,Nadiya Bakhiya,Carla F. C. Fernandes,José R. Godoy,Hansruedi Glatt,Ernst Petzinger +8 more
TL;DR: Human sodium-dependent organic anion transporter (SOAT) cDNA, which consists of 1502 bp and encodes a 377-amino acid protein, is cloned and exhibits a seven-transmembrane domain topology with an outside-to-inside orientation of the N- terminal and C-terminal ends.
92
Frequency of the nt230 (del4) MDR1 mutation in Collies and related dog breeds in Germany.
TL;DR: Considering the predominant role of MDR1 P-glycoprotein in drug disposition and in particular for blood-brain barrier protection, MDR 1 genotype-based breeding programs are recommended for improving the safety of drug therapy in these canine breeds.
82